within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EJ03_Pacritinib;

model Pacritinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 5.500000000000001e-06,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.267,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.013166666666666667,
    Tlag = 18.6,
    Vdp = 0.467,
    k12 = 1.388888888888889e-05,
    k21 = 1.388888888888889e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Pacritinib</td></tr><tr><td>ATC code:</td><td>L01EJ03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>267</td><td>L</td></tr>
    <tr><td>clearance:</td><td>19.8</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pacritinib is an oral, selective inhibitor of Janus-associated kinases JAK2 and FLT3 used for the treatment of myelofibrosis, particularly in patients with thrombocytopenia. It is approved for use in several countries for adults with intermediate- or high-risk primary or secondary myelofibrosis.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters reported in adult patients with myelofibrosis, following oral administration as part of clinical development.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EJ03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Pacritinib;
